Compare CYTK & DUOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | DUOL |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.8B |
| IPO Year | 2004 | 2021 |
| Metric | CYTK | DUOL |
|---|---|---|
| Price | $68.45 | $191.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 17 |
| Target Price | $77.87 | ★ $331.67 |
| AVG Volume (30 Days) | 1.9M | ★ 2.7M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 338.81 |
| EPS | N/A | ★ 8.04 |
| Revenue | $87,211,000.00 | ★ $964,271,000.00 |
| Revenue This Year | $363.61 | $38.90 |
| Revenue Next Year | $64.33 | $25.89 |
| P/E Ratio | ★ N/A | $23.82 |
| Revenue Growth | ★ 2609.26 | 39.86 |
| 52 Week Low | $29.31 | $166.27 |
| 52 Week High | $69.33 | $544.93 |
| Indicator | CYTK | DUOL |
|---|---|---|
| Relative Strength Index (RSI) | 62.93 | 35.82 |
| Support Level | $59.85 | $167.47 |
| Resistance Level | $67.98 | $192.80 |
| Average True Range (ATR) | 2.72 | 9.46 |
| MACD | 0.13 | 3.71 |
| Stochastic Oscillator | 91.35 | 65.14 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Duolingo Inc is a technology company that develops a mobile learning platform to learn languages and is the top-grossing app in the Education category on both Google Play and the Apple App Store. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue; time-based subscriptions, in-app advertising placement by third parties, and the Duolingo English Test, and In-App Purchases.